Thursday, July 9, 2026

Patent intelligence · US

US 12152061

T-cell modulatory multimeric polypeptides and methods of use thereof

granted A61KA61K2039/505A61K2039/55533A61K35/17
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 30
Patent details — US 12152061
Jurisdiction
US
Status
granted
Grant date
Nov 26, 2024
Expiration
Nov 21, 2044
Claims
20
CPC classes
A61K, A61K2039/505, A61K2039/55533, A61K35/17
View on Google Patents ↗

Quick answer

US 12152061 (T-cell modulatory multimeric polypeptides and methods of use thereof) is held by Cue Biopharma, Inc.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K2039/505, A61K2039/55533, A61K35/17, A61K38/00, A61K39/12

More from Cue Biopharma, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421287

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Sep 18, 2045

    granted
  2. US 12257311

    Multimeric T-cell modulatory polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Mar 20, 2045

    granted
  3. US 12180258

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Dec 26, 2044

    granted
  4. US 12145973

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Expires Nov 14, 2044

    granted
  5. US 12029782

    MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof

    Cue Biopharma, Inc. · Expires Jul 4, 2044

    granted
  6. US 12006348

    T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof

    Cue Biopharma, Inc. · Expires Jun 6, 2044

    granted
  7. US 11993641

    Methods for modulating an immune response

    Cue Biopharma, Inc. · Expires May 23, 2044

    granted

Frequently asked questions

What is US patent 12152061?

US 12152061 (T-cell modulatory multimeric polypeptides and methods of use thereof) is held by Cue Biopharma, Inc.. Status: granted. Granted Nov 26, 2024. Expires Nov 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12152061?

Cue Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.

When does US 12152061 expire?

Our index shows an expiration date of Nov 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.